StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO – Free Report) in a research note issued to investors on Sunday. The brokerage issued a sell rating on the medical device company’s stock.
NeuroMetrix Stock Performance
Shares of NeuroMetrix stock opened at $3.23 on Friday. The stock has a market cap of $3.46 million, a PE ratio of -0.59 and a beta of 2.22. The firm has a 50-day moving average of $3.33 and a 200-day moving average of $4.59. NeuroMetrix has a 52-week low of $2.85 and a 52-week high of $15.04.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of NURO. Vanguard Group Inc. raised its stake in NeuroMetrix by 6.7% during the first quarter. Vanguard Group Inc. now owns 315,137 shares of the medical device company’s stock worth $1,311,000 after acquiring an additional 19,667 shares in the last quarter. Virtu Financial LLC acquired a new position in NeuroMetrix during the first quarter worth about $78,000. Northern Trust Corp acquired a new position in NeuroMetrix during the second quarter worth about $41,000. Renaissance Technologies LLC raised its stake in NeuroMetrix by 46.4% during the second quarter. Renaissance Technologies LLC now owns 44,113 shares of the medical device company’s stock worth $162,000 after acquiring an additional 13,985 shares in the last quarter. Finally, Citadel Advisors LLC raised its stake in NeuroMetrix by 44.3% during the third quarter. Citadel Advisors LLC now owns 34,699 shares of the medical device company’s stock worth $97,000 after acquiring an additional 10,652 shares in the last quarter. Institutional investors and hedge funds own 5.07% of the company’s stock.
NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies.
- Five stocks we like better than NeuroMetrix
- 3 Monster Growth Stocks to Buy Now
- MarketBeat Week in Review – 2/5 – 2/9
- The How And Why of Investing in Oil Stocks
- Cloudflare results spark analysts reset: 25% upside ahead
- Basic Materials Stocks Investing
- Beyond Nvidia: The hidden stars with 200% earnings growth
Receive News & Ratings for NeuroMetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix and related companies with MarketBeat.com's FREE daily email newsletter.